

CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

05.08.2016

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code: CAPLIPOINT.

By NEAPS

Dear Sirs.

SUB: Press Release

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find the enclosed copy of communication being released to the press today.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited

Company Secretary

Ph.: +9197884 59333/69333



CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

PRESS RELEASE

FIRST ANDA FILED WITH US FDA FOR INJECTABLES

Results - Q1 FY 17

Chennai, August 05, 2016: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter (Q1 FY 17) ended June 30, 2016.

Key Financial & Performance Highlights - Consolidated

INR Lacs

Details	Q1 FY 17	Q1 FY 16	Growth %	FY 16 (9M)	FY 15	Growth (Annualised)
Gross Revenue	8,508	7,013	21%	23872	25177	26%
EBITDA	2383	1964	21%	6820	6200	45%
EBITDA %	28%	28%		28%	25%	
PAT	1614	1265	28%	4633	4104	49%
PAT%	19%	18%		19%	16%	

Key Financial & Performance Highlights - Standalone

INR Lacs

	HAIN					
Details	Q1 FY 17	Q1 FY 16	Growth %	FY 16 (9M)	FY 15	Growth (Annualised)
Gross Revenue	7,955	6755	18%	23129	24023	28%
EBITDA	2169	1930	12%	6634	5930	48%
EBITDA %	27%	29%		29%	25%	
PAT	1442	1263	14%	4,589	4094	48%
PAT %	18%	18%		20%	17%	

The company continues its strong performance with revenue growing 21% and PAT up 28% compared to the correspoding quarter 2015-16. Emerging markets continue to perform well for the company, with a new order for INR 5+ crore being received from Venezuela, for which the full payment has been received in advance. This is in addition to the INR 24 crore supplied to Venezuela in 2015-16, for which also, the payment has ABBEEN received in full.

Unit 1: No: 83/05 Buthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: +91 413 2674046 / 4047

Unit II: No.18, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District. Pincode - 601 201 Ph.: +91 44 27900901 Unit IIIX KHASRA No.435,Village Suraj Majra, N.H. No.21,Baddi, Teh. Nalagarh, District Solan, Himachal Pradesh — 173205. Ph.: +91 1795 245512

Unit IV: Survey No.: 895 & 897, Guruvarajakandigai, Sirupuzhalpettai (Post.), Gummidipoondi Taluk, Thiruvallur District, Pincode - 601 201

Ph.: +9197884 59333/69333

CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

Emerging Markets

Company has added another 70 new product registrations in this Quarter, taking the total tally to over 2000 active registrations as on date. Approval for another 260 products are expected in the next 3-4 Quarters.

As part of its expansion strategy going forward, the Company has completed the setup of its subsidiary in Hong Kong and will shortly be setting up its next subsidiary in Colombia.

Regulated Markets

Company is happy to announce that the first ANDA has been filed in July and GDUFA fees will be paid in September for the impending US FDA inspection. Company is targeting the next ANDA filing in Q2-2016-17 while also working on 7 more ANDAs to be filed by Q2-2017-18.

Company has also filed dossiers in Brazil and Colombia in the last 9 months, and further filings are planned in the near future.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 2000 product licenses across Latin America and Africa, with another 260 in the pipeline. The company is entering into the regulated markets for injectables, having already been approved by EU and Brazil and expecting US FDA approval in the near future.

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

CHENNAI-17